Dr. Reddy's Stock Dips as Phase III Lung Cancer Trial Halted

Introduction: A Major Setback in Oncology Pipeline

Dr. Reddy’s Laboratories Ltd announced on Friday, March 13, that its subsidiary will discontinue the Phase III TACTI-004 trial for eftilagimod alfa, an investigational drug for first-line non-small cell lung cancer. The decision came after a recommendation from the Independent Data Monitoring Committee (IDMC), leading to an immediate negative reaction in the market. Shares of the Hyderabad-based pharmaceutical company fell by 2.30% on the BSE, reflecting investor concern over the future of this key pipeline asset.

The Independent Committee's Recommendation

The halt was not unexpected but followed a structured process. The IDMC's advice was based on a planned interim futility analysis, a standard checkpoint in clinical trials designed to determine if a drug candidate is likely to achieve its intended efficacy endpoints. The results of this analysis indicated that the trial was unlikely to succeed, prompting the recommendation to stop enrolling new patients. In response, Dr. Reddy’s and its partner, Immutep Limited, confirmed they will implement an orderly wind-down of the trial. This process includes ensuring appropriate follow-up for existing patients and closing trial sites in line with all regulatory and ethical standards.

Immediate Market Impact

The news directly impacted Dr. Reddy's stock performance. On March 13, 2026, the company's shares closed at ₹1,288.40 on the BSE, a decline of ₹30.35, or 2.30%. This drop underscores the high stakes associated with late-stage clinical trials, where negative outcomes can significantly affect a company's valuation and investor sentiment. The halt represents a considerable setback for a program that was once viewed as a promising addition to Dr. Reddy's oncology portfolio.

Background of the Licensing Agreement

The trial's discontinuation is particularly disappointing given the significant investment and strategic importance of the partnership with Immutep. In December 2025, Dr. Reddy’s Laboratories SA entered into an exclusive licensing agreement with Immutep SAS. The deal granted Dr. Reddy's the rights to develop and commercialize eftilagimod alfa in all global markets except North America, Europe, Japan, and Greater China. The agreement, valued at over $170 million, included an upfront payment and potential future milestone payments and royalties. At the time, M.V. Ramana, CEO of Branded Markets, expressed high hopes for the drug's potential to set a new standard of care in lung cancer treatment.

About Eftilagimod Alfa (efti)

Eftilagimod alfa is a first-in-class immunotherapy designed to activate the immune system to fight cancer. Unlike existing immune checkpoint inhibitors that work by releasing the brakes on the immune system, efti acts as an activator. The drug was being evaluated not only for non-small cell lung cancer (NSCLC) but also for other indications like head and neck cancer, breast cancer, and soft tissue sarcoma. Its potential was recognized by the U.S. Food and Drug Administration (FDA), which had granted it Fast Track designation for both first-line NSCLC and head and neck squamous cell carcinoma (HNSCC), highlighting the unmet medical need it aimed to address.

A Pattern of Regulatory Hurdles

This clinical trial setback adds to a series of recent challenges for Dr. Reddy's in bringing complex new drugs to market. The company has faced other delays, including for its rituximab biosimilar, where a launch is now considered unlikely in the near term due to ongoing regulatory processes that began after observations at a facility in 2023. Similarly, the launch of AVT03 has been pushed to the second quarter of FY27 or later due to manufacturing facility issues cited by the FDA. While these delays are unrelated to the eftilagimod alfa trial, they form a broader context of the regulatory and developmental hurdles the company is navigating.

Key Trial and Financial Details

Next Steps for the Program

Following the halt, both Dr. Reddy's and Immutep have committed to a comprehensive review of the trial data. The goal is to gain a deeper understanding of the clinical results and determine the appropriate path forward for the eftilagimod alfa program. In its official statement, Dr. Reddy's emphasized that patient safety and regulatory compliance remain its highest priorities. The company will continue to engage with Immutep to evaluate the study outcomes and decide on the future of their collaboration for this specific asset.

Conclusion

The discontinuation of the Phase III trial for eftilagimod alfa is a significant clinical and financial setback for Dr. Reddy's Laboratories. It removes a promising late-stage asset from its immediate oncology pipeline and raises questions about the future of its multi-million dollar licensing deal with Immutep. The company's focus now shifts to analyzing the trial data to salvage any potential learnings while navigating other regulatory challenges across its broader portfolio. The future of the eftilagimod alfa program now depends entirely on the insights gleaned from this comprehensive data review.